# 119-hr-5139: EPIPEN Act

119-hr-5139, EPIPEN Act, is a 119th Congress bill sponsored by Rep. Frost, Maxwell [D-FL-10] (D-FL); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-hr-5139
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-5139
- Congress: 119
- Title: EPIPEN Act
- Status: introduced
- Introduced: 2025-09-04
- Sponsor: Rep. Frost, Maxwell [D-FL-10] (D-FL)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**Caps in-network out-of-pocket costs for FDA-approved epinephrine delivery systems across major federal health plans.** This bill would require group and individual plans governed by the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code to cover epinephrine delivery systems with no deductible and cost sharing capped at $60 per package of two devices, with those payments counting toward plan deductibles and out-of-pocket maximums. - Families and patients: People who need epinephrine would pay at most $60 for a two-pack in-network, and those payments would count toward their deductible or out-of-pocket maximum. Coverage applies to any FDA-approved delivery system, including auto-injectors, nasal sprays, and approved sublingual devices. - Employers and group plans: Plans subject to ERISA or the Public Health Service Act would have to adopt the no-deductible rule and the $60 in-network cap for plan years beginning on or after January 1, 2026. - Insurers and network rules: The cap applies to in-network coverage; plans may set different, potentially higher, cost sharing for out-of-network epinephrine delivery systems.

## Cosponsors (1)

- Rep. Matsui, Doris O. [D-CA-7] (D-CA), 2025-09-04T00:00:00.000Z

## Provisions PRIA read

- Lower epinephrine costs for insured people: benefit, low. If enacted, group and individual health plans would have to cover FDA‑approved epinephrine devices. You would not owe a deductible for these devices. Your share would be capped at $60 for a 2‑pack (or the equivalent). What you pay would still count toward your plan deductible and out‑of‑pocket limi…

## Related bills

- 119-hr-9877: Health Equity and Accountability Act of 2026
- 119-hr-3816: Weather Act Reauthorization Act of 2025
- 119-hr-7977: Energy Bills Relief Act
- 119-hr-4669: FEMA Act of 2025
- 119-hr-7973: Momnibus Act
- 119-hr-3077: Agriculture Resilience Act of 2025

## Sources
- [119-hr-5139 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/5139)

## Related
- [119-hr-9877: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-hr-9877)
- [119-hr-3816: Weather Act Reauthorization Act of 2025](https://policyrisk.com/legislation/119-hr-3816)
- [119-hr-7977: Energy Bills Relief Act](https://policyrisk.com/legislation/119-hr-7977)
- [119-hr-4669: FEMA Act of 2025](https://policyrisk.com/legislation/119-hr-4669)
- [119-hr-7973: Momnibus Act](https://policyrisk.com/legislation/119-hr-7973)
- [119-hr-3077: Agriculture Resilience Act of 2025](https://policyrisk.com/legislation/119-hr-3077)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-5139 (as of 2026-04-21).